Whats new
Whats new.
CLSA Equity Research - Immutep FY22 Result: Cash runway to early-CY24; may prioritise 1L NSCLC trial (which is in combo with Keytruda) (ASX:IMM) (Analyst: Andrew Paine)
August 31st 2022
For a copy of this analyst report please contact your CLSA advisor